Life
Science

Physics & Engineering

 

Sortieren nach: Datum | Licensing Manager
Home › Technology Offers
Es wurden 5 Technologieangebote gefunden

Cytokinin Receptor Antagonists and Compositions Containing these Derivatives


08.12.2011 | Ref.Nr. 07114
Download as PDF PDF Download Share
Life Science › Nutrition

Generel formular of alylbenzylamino Picture: WO 2009/043320 A2 Background
Cytokinins are plant hormones involved in cell division, shoot meristem and leaf formation, chloroplast biogenesis, and senescence. The development of agonists and antagonists with a particular physiological effect is useful in mechanism-of-action studies of biologically active natural products. The potent naturally occurring cytokinin N6-isopentenyladenine served as the basis for initial structure-activity studies.

Technology
We offer substituted 6-(alkylbenzylamino)-purin derivatives as cytokinin receptor antagonists to provide cytokinin analogons for growth regulation in plants and to offer the possibility for a specific selectivity for cytokinin receptors without being toxic for animal cells. The derivatives can be used to influence morphology, leading to:
  • Increased root growth, fruit or grain size
  • Stimulation of root branching and enhanced number of lateral roots
  • Accelerated seed germination
  • Enhanced yield and quality of crops

 
IP Rights
Czech Patent Application was filed in 2007
PCT Patent Application was filed in 2008
National applications filed in USA and Europe

Patent Owner

  • Freie Universität Berlin
  • Palacky University Olomouc (CZ)
Application Area:
Applicable as plant growth regulator
Development Stage: Green house (plant model Arabidopsis thaliana)
Schlagworte: 6-(alkylbenzylamino)-purin derivatives, cytokinin analogons, cytokinin receptor antagonist, Plant Growth Regulator, purin derivatives,
Weitere Kategorien: Life Science, Nutrition
Bild des Benutzers Dr. Bettina Büttner
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Suitable Industry: Agriculture industry
Benefits:
  • Non toxic for animal cells
  • Efficiency is proven in various test systems
  • Suitable regulator for proliferation and morphogenesis in tissue culture

Peptides for Diagnosis and Therapy of Celery Allergy and of Hazelnut Allergy


10.11.2010 | Ref.Nr. 10048
Download as PDF PDF Download Share
Life Science › Diagnostics

Novel linear IgE-binding peptide epitopes of the major celery allergen api g1 have been identified which are suitable for the diagnosis and therapy of celery allergy. The peptide epitopes can also serve as a basis for the detection of api g1 allergens in food and other  products. Based on the novel peptides, a high specific assay was developed which allows to distinguish between celery allergic patients and healthy individuals.

Celery is a frequent cause of food allergy in pollen-sensitized patients and may induce severe allergic reactions. Allergic reactions against celery are of major clinical relevance due to celery's wide presence in convenience foods and spice. Approximately 3% - 4% of the European or American population and 5% of young children are affected by immunoglobulin E (IgE)  mediated food allergy; 30% of them are sensitized to celery. The symptoms ranging from mild oral pruritus to a possible life-threatening anaphylactic shock.

IP Rights
An EP application was filed in July 2010.

Origin
The invention was made at the Charité – Universitätsmedizin Berlin.

Application Area:
Pharma, Diagnostic, Food analytic
Development Stage: Pilot study, in vitro
Type of Collaboration: Licence
Schlagworte: Allergen, Allergy, Celery, Diagnosis, Food, Hazelnut, Peptide, Therapy,
Weitere Kategorien: Diagnostics, Immunology & Infection, Nutrition, Pharma & Biotech
Bild des Benutzers Dr. Bettina Büttner
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Market Potential: Worldwide
Benefits:
  • Allows a specific and fast identification of the api 1g allergen in celery allergic patients
  • More reliable results compared to PCR- or state of the art- IgE-detection approaches are supposed
  • Peptide is suitable for chip applications and automatable methods
  • The novel peptides can be used for the desensitization of patients (Immunotherapy)

Novel Compounds for Cytokinin Oxidase Inhibition in Plants


18.02.2010 | Ref.Nr. 06075
Download as PDF PDF Download Share
Life Science › Nutrition

Internal cytokinin levels influence growth and morphology in higher plants. The amount of cytokinin present in a plant or plant tissue is strongly controlled by a signalling pathway involving cytokinin oxidase (CKX) as one major component. Antisense inhibition of CKX activity leads to a stimulation of root growth, retardation of senescence and the production of a higher number of inflorescences. The novel class of substituted 6-anilinopurine derivatives inhibiting CKX activity leads to a similar effect on higher plants as the antisense technique.

IP Rights
Czech patent application PV 2007-453 filed on July 7, 2007, PCT patent application filed on July 2, 2008. Regionalization in 2010.

Origin
The invention was made at the Freie Universität Berlin (Germany) in cooperation with the Palack University Olomouc.
Application Area:
Agriculture, Cosmetics
Development Stage: Experiments in model plant Arabidopsis, tabacco and first results in rape
Type of Collaboration: License
Schlagworte: CKX Inhibition, Cytokinin Oxidase, Plants Growth, Purin Derivates, Senescence Retardation,
Weitere Kategorien: Life Science, Nutrition
Bild des Benutzers Dr. Bettina Büttner
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Market Potential: Worldwide
Benefits:
  • Application in agriculture and cosmetics
  • Plant growth stimulator: Increases bio mass and size of flower organs in Arabidopsis. In rape: Increases branching, more fruits per plant
  • Delaying senescence in plants and mammalian skin cells (fibroblasts and keratinocytes)
  • Higher yield in crops Chemical synthesis is proven
  • Improved selectivity and efficiency in CKX-inhibition than common cytokinin derivatives
  • Less toxic than known purine derivatives

rock2 and rock3, two new gain-of-function variants of the cytokinin receptors AHK2 and AHK3


18.02.2010 | Ref.Nr. 07116
Download as PDF PDF Download Share
Life Science › Nutrition

The productivity of a plant can be influenced in various different ways, e.g. by improving plant growth characteristics or by delaying leaf senescence. Cytokinins are a class of plant hormones controlling numerous aspects of plant development throughout the life cycle.
The present invention relates to two novel gain-of-function variants of the cytokinin receptors AHK2 and AHK3, namely rock2 and rock3 of Arabidopsis, to transgenic organisms comprising at least one of said new gain-of-function cytokinin receptor variants and to a method for the manufacturing of a transgenic plant comprising at least one of the new gain-of-function variants.

Compared to wild-type the Arabidopsis rock2 and rock3 mutants show:
  • enhanced vegetative growth
  • >75% increase of fresh weigth at 18 days after germination
  • 43% increase of rosette size

Shoot height, fresh weight of stems, the number of siliques on the main stem and the number of siliques per plant were all increased between 18% and 31% in Arabidopsis rock2 mutants compared to wild-type. Transgenic rock2- or rock3- overexpressing Arabidopsis plants show increased shoot height, a higher number of siliques per plant, thicker stems and bigger flowers.

IP Rights
A European Patent application was filed in July 2009.

Origin
The technology was developed at the Free University of Berlin (Germany).

Application Area:
Agriculture
Development Stage: Model plant Arabidopsis
Type of Collaboration: License
Schlagworte: AHK2, AHK3, Cytokinin Receptor, gain-of-function, Plant Growth, Transgenic Plant,
Weitere Kategorien: Life Science, Nutrition
Bild des Benutzers Dr. Bettina Büttner
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Market Potential: Worldwide
Benefits:
  • Novel gain-of-function variants of the cytokinin receptors AHK2 and AHK3
  • Generation of transgenic rock2 and/or rock3 plants with improved productivity and/or growth characteristics

Polygenic Mouse Model for Juvenile Obesity Research


30.10.2008 | Ref.Nr. 09001
Download as PDF PDF Download Share
Life Science › Pharma&Biotech › Metabolism

We offer a set of well-characterized polygenic mouse models that allow the test of drugs for weight loss and the targeted search for genetic factors influencing fat deposition. We offer two animal groups: The Berlin Fat Mouse (BFM) outbred population and the Berlin Fat Mouse Inbred 860 (BFMI860) strain.

BFM has been selected for high fatness and low protein content from a base population of animals bought in several Berlin pet shops. BFMI860 is an inbred derivate of BFM that has been generated by repeated matings of most obese BFM full-sibs after 58 generations of selection. BFM and BFMI860 develop extreme body weight with high body fat mass, but only marginal increased body lean mass. The phenotype is visible already at a very early age. Highest weight gain occurs between 6 and 10 weeks. At standard diet, the adult animals of the BFMI860 strain had a body fat percentage of 22 to 30% in males and 28 to 37% in females compared to 6% in wildtype mice. The animals respond to high fat diet with further increase of adiposity. BFMI860 mice show several features of the metabolic syndrome. Consistent with the high genetic variability, BFM animals have a higher variability in the fat percentage and related phenotypes than BFMI860.


Origin
The development was made by the Humboldt-Universität zu Berlin.

Application Area:
Metabolism, Pharmaceutical Research
Development Stage: Product
Type of Collaboration: License
Schlagworte: Fat, Obesity, Polygenic Mouse Model,
Weitere Kategorien: Life Science, Nutrition, Research Tools, Pharma & Biotech, Metabolism
Bild des Benutzers Dr. Bettina Büttner
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Market Potential: Worldwide
Benefits:

The BFM population and the BFMI860 mouse strain are excellent models to study

  • development of obesity and related traits
  • response to different diets
  • response to drugs inhibiting obesity
  • genes regulated after treatment of obesity or by different diets
  • gene interaction between obesity genes and disease genes related to obesity